Voyager Therapeutics (NASDAQ:VYGR) Downgraded by StockNews.com to Hold

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Several other analysts have also recently weighed in on the stock. Wedbush started coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Citigroup began coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Performance

NASDAQ VYGR traded up $0.02 during mid-day trading on Friday, reaching $6.27. 372,967 shares of the stock were exchanged, compared to its average volume of 632,306. The stock has a market capitalization of $342.53 million, a PE ratio of 8.83 and a beta of 0.90. The business’s fifty day simple moving average is $6.59 and its 200 day simple moving average is $7.17. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. On average, analysts anticipate that Voyager Therapeutics will post -0.89 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. raised its holdings in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares in the last quarter. SummerHaven Investment Management LLC grew its position in Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after purchasing an additional 1,921 shares during the last quarter. Hunter Perkins Capital Management LLC increased its position in Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after acquiring an additional 2,025 shares during the period. Empowered Funds LLC raised its stake in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after acquiring an additional 2,638 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.